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Background
Sarcoidosis is an idiopathic granulomatous disease that
can affect any organ system, including the heart. We
examined the predictive relationship of CMR imaging and
clinical parameters with major adverse cardiac events
(MACE) in patients with sarcoidosis.
Methods
A consecutive series of 93 study subjects undergoing clini-
cal CMR for evaluation of cardiac sarcoidosis from 2002
to 2012 were identified from the CMR reporting database.
All studies were performed using a 1.5T CMR system
(Philips Achieva). Anatomic, functional and late gadoli-
nium enhanced (LGE) images were acquired and analyzed
according to standard clinical protocols. Clinical data were
derived from the medical record. Vital status was con-
firmed using medical record and the Social Security
Administration Death Master File. MACE was defined as
mortality, ventricular arrhythmia, or device placement.
Relationship to MACE was evaluated using proportional
hazards regression.
Results
The cohort characteristics are shown in the table. Evi-
dence of extracardiac sarcoidosis was present in 81(87%)
and proven by biopsy in 39(42%). MACE occurred in 28
(30%); 7(8%) died, 16(17%) had ventricular arrhythmia,
and 11 (12%) underwent device placement. Analysis
results are shown in the Table, including elements of the
Japanese Ministry of Health guidelines for diagnosis of
cardiac sarcoidosis revised in 2006 and imaging measure-
ments. CMR measures associated with MACE include left
and right atrial size, and left ventricular cavity size, mass,
and function. LGE had a borderline association with
MACE but was not associated with mortality. Study
subjects who received steroid therapy had a reduction in
MACE that was borderline significant but with no appar-
ent reduction in mortality.
Conclusions
In this cohort of consecutive patients with sarcoidosis
referred for CMR, measures of left and right atrial size,
and left ventricular size, mass and function were highly
predictive of both MACE and mortality. LGE was border-
line associated with MACE but not predictive of mortality.
Steroid therapy had a trend toward reduction of MACE
but no influence on mortality. These data support the role
of CMR in the routine evaluation of all patients with
suspected cardiac sarcoidosis.
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Table 1 Characteristics of the study cohort and associations with adverse cardiac events and mortality
Major Adverse Cardiac Event Mortality
Variable Value Hazard Ratio P Hazard Ratio P
Age,y* 52 ± 11 1.3(0.9-1.8) 0.168 2.1(1.1-4.4) 0.033
Male 51(55%) 1.4(0.7-3.1) 0.350 0.7(0.15-3.0) 0.601
AV block+ 7(8%) 8.8(3.5-21.9) < 0.001 6.1(1.2-31.4) 0.032
Basal LV thinning+ 3(3%) Not defined 0.989 Not defined 0.995
LV ejection fraction < 50%+ 17(18%) 3.1(1.4-6.5) 0.004 6.2(1.4-27.5) 0.018
Ventricular ectopy+ 9(10%) 5.0(2.1-11.9) < 0.001 Not defined 0.995
Right bundle branch block+ 16(17%) 3.2(1.4-7.1) 0.005 4.9(1.1-22.3) 0.038
Axis deviation+ 19(20%) 2.4(1.4-4.2) 0.002 3.4(1.3-8.9) 0.011
Pathologic Q waves+ 7(8%) 4.1(1.7-10.2) 0.002 14.6(3.2-66.9) < 0.001
LV wall motion abnormality+ 11(12%) 3.1(1.3-7.3) 0.011 10.1(2.3-45.2) 0.003
Heart failure 13(14%) 2.5(1.1-5.8) 0.027 4.8(1.1-21.7) 0.040
Coronary artery disease 6(6%) 2.0(0.6-6.5) 0.267 7.8(1.5-40.6) 0.014
Diabetes mellitus 12(13%) 0.8(0.2-2.6) 0.678 1.1(0.1-9.4) 0.912
Hypertension 33(35%) 2.1(1.0-4.3) 0.056 12.2(1.5-101.6) 0.021
Left atrial AP dimension, mm* 35 ± 8 1.0(0.6-1.5) 0.940 3.6(1.7-7.6) < 0.001
Right atrial 4-chamber dimension, mm* 51 ± 8 0.7(0.4-1.2) 0.193 2.4(1.0-5.3) 0.040
LV end diastolic volume, ml* 163 ± 46 1.1(1.0-1.2) 0.001 1.2(1.1-1.4) 0.007
LV end diastolic volume index, ml/m2* 82 ± 20 1.4(1.2-1.6) < 0.001 1.4(1.1-1.9) 0.010
LV end systolic volume, ml* 89 ± 40 1.1(1.1-1.2) < 0.001 1.3(1.1-1.4) < 0.001
LV ejection fraction,%* 57 ± 11 0.6(0.5-0.8) 0.001 0.5(0.3-0.8) 0.008
LV mass, g* 111 ± 42 1.1(1.0-1.2) 0.056 1.3(1.1-1.5) < 0.001
RV end diastolic volume, ml* 154 ± 42 1.0(1.0-1.1) 0.318 1.1(0.9-1.3) 0.446
RV end diastolic volume index, ml/m2* 77 ± 16 1.2(1.0-1.5) 0.074 1.3(0.8-2.1) 0.393
RV end systolic volume, ml* 69 ± 28 1.1(1.0-1.2) 0.236 1.2(1.0-1.4) 0.100
RV ejection fraction, %* 56 ± 7 0.8(0.5-1.4) 0.474 1.0(0.3-3.4) 0.950
Presence of LGE+ 15(16%) 2.2(0.9-5.2) 0.072 0.9(0.1-7.8) 0.956
Number of segments with LGE 1 ± 3 1.1(1.0-1.3) 0.042 1.2(0.9-1.4) 0.204
Steroid therapy 37(40%) 0.5(0.2-1.1) 0.087 2.7(0.5-14.9) 0.248
*Hazard ratio shown for a 10 unit change.
+Included in the Japanese Ministry of Health guideline for the diagnosis of cardiac sarcoidosis, revised 2006.
Abbreviations as in the text.
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